AML Stem Cell Targeting, ADC Development, and High-Purity Reagents for Myeloid Malignancies
Target Overview
CLEC12A (also known as CD371) is a C-type lectin domain-containing protein encoded by the CLEC12A gene. It functions as an inhibitory receptor and is selectively expressed on acute myeloid leukemia (AML) blasts and leukemic stem cells (LSCs) but absent on normal hematopoietic stem cells. This expression pattern makes it a superior therapeutic target compared to CD33. A single-nucleotide polymorphism (rs479499) has been documented in the CLEC12A gene (UniProt Q5QGZ9).
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CLEC12A drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CLEC12A ECD-Fc Fusion Protein. High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). | View CLEC12A Products |
| Gene Delivery | CLEC12A Lentivirus Premade Particles. Full-length ORF for stable AML cell line construction. High titer. | View CLEC12A Products |
| Benchmark Ab | Anti-CLEC12A (Clone CLT03 Biosimilar). Recombinant positive control for LSC targeting. | View CLEC12A Products |
| Validator | CLEC12A siRNA Set. For knockdown verification and specificity controls. | View CLEC12A Products |
| Counter-Screen | CLEC12B (CLEC-1) Protein. Critical homology control for selectivity assays. | View CLEC12B Products |
| Synergistic Target A | CD33 (Siglec-3). Co-expression on AML blasts; dual-targeting strategies. | View CD33 Products |
| Synergistic Target B | CD123 (IL-3Rα). Alternative LSC marker; comparative validation. | View CD123 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse preclinical evaluation | Human/Cyno/Mouse CLEC12A ECD proteins available with >95% purity; endotoxin controlled for in vivo compatibility. |
| CLEC subfamily counter-screening (including CLEC12B) | Homolog panel proteins (e.g., CLEC7A, CLEC9A, CLEC12B) strictly sequence-verified for selectivity assays. |
| ADC Internalization rate & epitope discrimination | ECD-Fc with native glycosylation (HEK293) preserves conformation for anti-stalk vs anti-CRD epitope discrimination; pH-sensitive dye uptake validation. |
| Lack of Controls / False Positives | Clinical benchmark antibodies (biosimilars) and validated siRNA included for specificity checks. |
Live CLEC12A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- View Active Clinical Trials (AML Focus)
- Latest ADC Internalization Research
- Recent Patent Filings (CLEC12A Targeting)
Global Clinical Landscape & Future Outlook
The race for CLEC12A therapeutics is intensifying, with major players shifting focus from traditional mAbs to ADCs, T-cell engagers (bispecifics), and myeloid-specific CAR-T constructs. As first-generation anti-AML stem cell therapies reach Phase I/II, the next wave of R&D is targeting optimized internalization rates for ADCs and high-avidity binding for cellular therapies. The differentiation battleground centers on selectivity over CLEC12B (endothelial expression) and optimization of internalization kinetics for payload delivery without off-target myelosuppression. Future strategies include dual-targeting (e.g., CLEC12A + CD33 or CD123) to overcome antigen escape.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | AstraZeneca (AZD0621), Academic Consortia | Relapsed/Refractory AML | Internalization Assay (ECD-Fc required for pH-sensitive dye uptake validation) |
| Bispecific (CD3-engager) | Merus, Johnson & Johnson, Emerging Biotech | AML / MDS | Cross-reactivity Panel (Need CLEC12B protein to verify selectivity) |
| Myeloid CAR-T | Celyad, SentiBio, Various Biotech | High-risk AML | Stable Cell Line Construction (Lentivirus) and Binding Avidity (HEK293 expressed proteins) |
| Naked mAb (LSC targeting) | University of Southampton (Originating IP) | AML Combination Therapy | Epitope Binning (Stalk vs CRD domain mapping using domain-truncated mutants) |